Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Where does TLT go from here?
View:
Post by gorpwood on Feb 07, 2022 8:14am

Where does TLT go from here?

The prospect of a COVID vaccine as well as a treatment for cancer is mindblowing.   But I have lost track of the timetable.   Assuming the research continues on its present track, how far away (months/years) is commercialisation both for COVID and for Bladder Cancer?
Comment by SouthernTierTom on Feb 07, 2022 8:16am
Read the Nr, it tells you what is next; These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus
Comment by SouthernTierTom on Feb 07, 2022 8:50am
Thanks "Sun" ; - ) I wonder how long they have to follow the hamsters to see if there is any negative effect? Bear in mind, we DO have vaccine options now, the urgency is much less so than it was 2 years ago. Also, question for you "Sun", would the animals be part of a deal?  You have suggested this potential "deal"....are the animals a throw in like the ...more  
Comment by Sunvalley on Feb 07, 2022 8:21am
In my view TLT will not live until commercialization. It will be gobbled up by a major before they will allow that to happen. With a two barreled approach  ie Covid / Cancer ,TLT now has the ability to "double your pleasure , double you fun" from now on ( For you youngsters ,A old doublemint gum commercial from the 1950,s )
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250